Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo
Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo
复制标题
DOI：
10.1128/jvi.79.9.5875-5879.2005
复制
发表时间：
2005-05-01
影响因子：
5.4
通讯作者：
Taguchi, H
中科院分区：
文献类型：
--
作者：
Daibata, M;Bandobashi, K;Taguchi, H
有目的的诱导eb病毒（EBV）裂解型感染联合更昔洛韦（GCV）治疗已被提倡作为EBV阳性b细胞淋巴瘤的新策略。我们证明了利妥昔单抗与地塞米松在诱导cd20阳性淋巴瘤细胞的溶性EBV感染方面具有协同作用。地塞米松/利妥昔单抗处理的细胞中加入GCV比单独使用地塞米松/利妥昔单抗在体外杀死ebv阳性淋巴瘤细胞和携带淋巴瘤的裸鼠中更有效，但在ebv阴性细胞中无效。这些数据表明，地塞米松/利妥昔单抗联合GCV诱导溶性EBV感染可能是EBV相关b细胞淋巴瘤的潜在病毒靶向治疗方法。
The purposeful induction of the lytic form of Epstein-Barr virus (EBV) infection combined with ganciclovir (GCV) treatment has been advocated as a novel strategy for EBV-positive B-cell lymphoma. We demonstrated that rituximab had a synergistic effect with dexamethasone on induction of the lytic EBV infection in CD20-positive lymphoma cells. Addition of GCV to the dexamethasone/rituximab-treated cells was more effective than dexamethasone/rituximab alone in killing EBV-positive lymphoma cells in vitro and in lymphoma-bearing nude mice but not in EBV-negative cells. These data suggest that induction of the lytic EBV infection with dexamethasone/rituximab in combination with GCV could be a potential virally targeted therapy for EBV-associated B-cell lymphoma.